Previous 10 | Next 10 |
Artivion Reports Second Quarter 2023 Financial Results PR Newswire Second Quarter and Recent Business Highlights: Achieved revenue of $89.3 million in the second quarter of 2023 versus $80.3 million in the second quarter of 2022, an increase of 11% on both a GA...
Artivion to Participate in Upcoming Investor Conferences PR Newswire ATLANTA , Aug. 1, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in thre...
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial Results PR Newswire ATLANTA , July 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, an...
2023-07-19 22:16:12 ET Summary Artivion, Inc. has begun to recover from the fallout after its PROACT trial failure. On-X sales almost doubled the 5-year average range in Q1, and management look to 15% CAGR in sales moving forward. Net-net, revise to buy, eyeing $24 initial obj...
2023-05-23 08:38:46 ET Artivion, Inc. ( NYSE: AORT ) announced Tuesday that the FDA cleared its premarket application (PMA) for PERCLOT Absorbable Hemostatic System, a clotting product the medical device maker has sold to Baxter International ( NYSE: BAX ). With the clea...
Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter PR Newswire Artivion to Receive $18.75 Million Milestone Payment Under Previously Announced Agreement Artivion to Begin Supplying Product to Baxter Under Transitional Manufacturing and Sup...
2023-05-07 11:49:08 ET Artivion, Inc. (AORT) Q1 2023 Earnings Conference Call May 4, 2023, 4:30 PM ET Company Participants Brian Johnston - Vice President, Gilmartin Group Pat Mackin - Chief Executive Officer Ashley Lee - Chief Financial Officer Conference ...
2023-05-04 17:40:00 ET Artivion press release ( NYSE: AORT ): Q1 Non-GAAP EPS of $0.02 beats by $0.04 . Revenue of $83.2M (+7.8% Y/Y) beats by $2.85M . The Company expects FY23 revenues to be in a range of between $337.0 million and $348.0 million, compared to ...
Artivion Reports First Quarter 2023 Financial Results PR Newswire First Quarter and Recent Business Highlights: Achieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first quarter of 2022, an increase of 8% on a GAAP basis a...
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results PR Newswire ATLANTA , April 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, an...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 12:00:05 ET Frank Takkinen from Loop Capital Markets issued a price target of $30.00 for AORT on 2024-07-02 08:49:00. The adjusted price target was set to $30.00. At the time of the announcement, AORT was trading at $26.015. The overall price target consensus ...
Artivion Amends Agreements with Endospan PR Newswire Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million , inclusive of loan off-set, and $100 m...